ENTA
$13.27
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Recent News
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conference to outline its evolving pipeline strategy, highlighting late-stage ambitions in respiratory syncytial virus (RSV) and a growing immunology and inflammation (I&I) portfolio built around small-molecul
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
WATERTOWN, Mass. AP) — Enanta Pharmaceuticals Inc. ENTA) on Monday reported a loss of $11.9 million in its fiscal first quarter.
JPM26: Enanta outlines strategy to lead in RSV therapeutics
Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.